Resistance of Cancer Cells to Ctl-Mediated Immunotherapy by Bonavida, Benjamin

Resistance of Cancer Cells to Ctl-Mediated Immunotherapy (Hardcover) (ISBN-13: 9783319178066)

Vendor: Benjamin Bonavida
Product type: Books
Format: Hardcover
$109.99
$109.99
$109.99
Subtotal: $109.99
Resistance of Cancer Cells to Ctl-Mediated Immunotherapy by Bonavida, Benjamin

Resistance of Cancer Cells to Ctl-Mediated Immunotherapy

$109.99
Resistance of Cancer Cells to Ctl-Mediated Immunotherapy by Bonavida, Benjamin

Resistance of Cancer Cells to Ctl-Mediated Immunotherapy

$109.99
Format: Hardcover
Description
Description
x
This comprehensive volume explores the latest research on the mechanisms of resistance in cancer cells to CTL-mediated immunotherapy. Chapter topics discuss cell-mediated immunity as the result of cytotoxic T-lymphocytes (CTL) directed specifically against cancer cells. In addition, the volume reviews how CTL mediate the cytotoxic activity, in large part, by the indication of apoptosis; hence, tumor cells develop anti-apoptotic mechanisms and thereby, resist CTL-induced apoptosis. In order for CTL-mediated antitumor immunotherapy to be effective, it is essential that agents directed against the resistant tumor cells sensitized cancer cells for CTL-mediated apoptosis. Examples of such agents discussed in the volume include are HDAC inhibitors, proteasome inhibitors, Bcl-2 family inhibitors, PARP, antibodies, and more.

Author: Benjamin Bonavida
ISBN-10: 3319178067
ISBN-13: 9783319178066
Publisher: Springer
Language: English
Published: 06/30/2015
Pages: 353
Format: Hardcover
Weight: 1.52lbs
Size: 9.21h x 6.14w x 0.81d
By Benjamin Bonavida
By Benjamin Bonavida
x

Benjamin Bonavida, Ph.D., is Professor, UCLA David Geffen School of Medicine for the Department of Microbiology, Immunology & Molecular Genetics. He is also Member, Department of Defense Congressionally Directed Medical Research Program, Member, National Cancer Institute SPORE Program, Member, International Scientific Advisory Board of the Israel Cancer Research Foundation, among other accomplishments. He is currently a scientific reviewer for several journals and a member of editorial boards including Journal of Clinical Immunology, International Journal of Oncology, and Cancer Biotherapy & Radiopharmaceuticals. He has published over 450 papers and reviews, has received more than 7,980 citations, and has edited four Springer volumes.

Salem Chouaib, Ph.D., is Head, Cancer Immunology Division at Institut Gustave Roussy. His research focuses on augmenting cytotoxic T cell immunity and studies how tumors evade the immune system. Dr. Chouaib has published more than 239 scientific papers and reviews, and has received more than 5,490 citations.

Recently Viewed Products